Welcome to our dedicated page for AIKI news (Ticker: aiki), a resource for investors and traders seeking the latest updates and insights on AIKI stock.
AIkido Pharma Inc. (AIKI), a biotechnology innovator since 1967, develops targeted cancer treatments and broad-spectrum antiviral therapies through academic collaborations. This page aggregates official announcements and analysis-worthy developments for stakeholders tracking the company's progress.
Access timely updates on clinical milestones, strategic partnerships with leading research institutions, and corporate initiatives like the active share repurchase program. Key focus areas include pancreatic cancer therapies, leukemia treatments, and novel antiviral platforms addressing multiple infectious diseases.
Regularly updated content covers licensing agreements, preclinical results, financial disclosures, and market expansion efforts. Bookmark this page to efficiently monitor AIkido Pharma's evolving role in oncology and virology research without navigating multiple sources.
Dominari Holdings Inc. (Nasdaq: DOMH) appointed George Way as Chief Financial Officer effective
DatChat has announced the launch of Habytat, a photorealistic metaverse featuring AI-powered pets. These virtual pets will mimic real-life interaction, growing from puppies and kittens to adults as users care for them. Users will be able to select from four dog breeds and two cat breeds for the initial launch in Spring 2023. The platform enhances user engagement through tasks such as feeding, training, and cleaning their pets. The initiative aims to democratize access to the metaverse and create a fun, interactive environment for pet lovers. For participation in breed selection, visit Habytat.io/pets.
Habytat, a metaverse platform by SmarterVerse Inc., a subsidiary of DatChat (NASDAQ: DATS), is launching early this spring, offering 200 artists complimentary virtual gallery spaces. This initiative aims to empower artists in showcasing and selling their work globally. The galleries will include technical support for digitizing physical art and integrating online sales, enhancing artists' online presence. Located in Habytat's Geniuz City, designed like Miami's Wynwood arts district, these galleries promote creativity and accessibility. Interested artists can apply through Habytat's website.
DatChat (NASDAQ: DATS) has appointed Wachsman as the agency of record for its subsidiary, Habytat by SmarterVerse, aimed at enhancing user engagement in the metaverse. CEO Darin Myman emphasized the goal of making metaverse technology accessible to a broader audience. Wachsman is recognized for its expertise in promoting innovative technologies and has received accolades from various industry publications. DatChat focuses on secure messaging and user privacy, providing a private social network that allows users control over their messages.
Dominari Holdings Inc. (Nasdaq: DOMH) has initiated a $2 million share repurchase program, with the first purchase of 4,000 shares at $3.1012 each completed on December 27, 2022. CEO Anthony Hayes emphasized that the stock is undervalued, aiming to enhance shareholder value through this program. The company plans to continue repurchasing shares based on market conditions and regulations. Dominari, transitioning to fintech, operates under its subsidiary, Dominari Financial Inc., while still developing its therapeutic portfolio through Aikido Labs, LLC.
AIkido Pharma Inc. has officially changed its name to Dominari Holdings Inc. and its ticker symbol from AIKI to DOMH, effective December 22, 2022. This decision was made during a board meeting on December 5, 2022. The rebranding aligns with the company's strategic shift from healthcare to financial services. Dominari is in the process of acquiring a registered broker-dealer and has allocated approximately $3.2 million towards this new subsidiary, Dominari Financial Inc., while also continuing to develop its existing therapeutic technology through AIkido Labs.